Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.58 | N/A | +5.90% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.58 | N/A | +5.90% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the earnings per share results, highlighting their commitment to shareholder value. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our shareholders.
This earnings report shows that Johnson & Johnson was able to exceed expectations on EPS, which may indicate strong operational performance. However, the lack of revenue data and guidance leaves some uncertainty about future growth. Investors will need to watch for more information in upcoming quarters to gauge the company's trajectory.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SERVISFIRST BANCSHAR
Jul 15, 2019